News
Zacks.com on MSN6m
Can Eli Lilly Keep Up as NVO Eyes First Oral Obesity Pill Approval?LLY's orforglipron study results disappoint, shifting investor focus to Novo Nordisk's bid for first FDA-approved oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback